92
Active Trials
32
Phase 1
44
Phase 2
34
Phase 3
13
Therapeutic Areas
Portfolio Concentration: 62% of active trials in Oncology
Oncology
57 active / 102 total
Multiple Myeloma
10 active
4 Ph3
11 total since 2015
NSCLC
8 active
2 Ph3
14 total since 2015
Non-Hodgkin Lymphoma
8 active
5 Ph3
10 total since 2015
Solid Tumor (Advanced)
7 active
1 Ph3
9 total since 2015
Melanoma
6 active
3 Ph3
11 total since 2015
Ovarian Cancer
4 active
4 total since 2015
ALL
3 active
1 Ph3
10 total since 2015
Squamous Cell Carcinoma
2 active
2 Ph3
9 total since 2015
Head and Neck Cancer
2 active
4 total since 2015
Prostate Cancer
2 active
3 total since 2015
Endometrial Cancer
2 active
2 total since 2015
Colorectal Cancer
1 active
1 total since 2015
Renal Cell Carcinoma
1 active
1 total since 2015
Hepatocellular Carcinoma
1 active
1 total since 2015
SCLC
0 active
2 total since 2015
Cervical Cancer
0 active
2 total since 2015
Neuroendocrine Tumors
0 active
2 total since 2015
Lung Cancer (General)
0 active
1 total since 2015
Merkel Cell Carcinoma
0 active
1 total since 2015
Triple Negative Breast Cancer
0 active
1 total since 2015
CLL
0 active
1 total since 2015
Brain Tumor
0 active
1 total since 2015
Hodgkin Lymphoma
0 active
1 total since 2015
Immunology
16 active / 39 total
Cardiovascular
12 active / 22 total
Metabolic
6 active / 23 total
Rare Disease
5 active / 10 total
Ophthalmology
2 active / 6 total
CNS
2 active / 2 total
Infectious Disease
1 active / 10 total
Respiratory
1 active / 9 total
Urology
1 active / 5 total
Renal
1 active / 1 total
Musculoskeletal
0 active / 9 total
Pain
0 active / 3 total
Click an indication to see competitive landscape (all sponsors in that indication).
Data: ClinicalTrials.gov (2015+)